Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: A pilot methodological study

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Liao, Christopher C L ^a,b   Mehta, Anuja ^b   Ward, Nicholas J ^a,b   Marsh, Simon ^a   Arulampalam, Tan ^a   Norton, John D ^b  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^b UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; TUMOR MARKER;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PILOT STUDY; POSTOPERATIVE PERIOD; PREDICTION; PROTEIN EXPRESSION; RECURRENCE RISK; AGED; ALGORITHM; BLOOD; COLORECTAL TUMOR; FEMALE; MALE; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; PROGNOSIS; PROTEOMICS;

AGED; AGED, 80 AND OVER; ALGORITHMS; BLOOD PROTEINS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77951214452     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-33     Document Type: Article

References (37)

1. Gravalos C, Garcia-Escobar I. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol 2009, 11:526-533. 10.1007/s12094-009-0397-8, 19661027.
2. Hind R, Rew DR, Johnson CD. Surgical excision alone is adequate treatment for primary colorectal cancer. Ann R Coll Surg Engl 1992, 74:63-67. 2497502, 1736798.
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. 10.1056/NEJMoa032709, 15175436.
4. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007, 12:38-50. 10.1634/theoncologist.12-1-38, 17227899.
5. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008, CD005390.
6. Morris EJA, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007, 56:1419-1425. 10.1136/gut.2006.116830, 17494107.
7. Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A. Current issues in adjuvant treatment of stage II colon cancer. Annal Surg Oncol 2006, 13:887-898.
8. Benson AB, Schrag D. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419. 10.1200/JCO.2004.05.063, 15199089.
9. Walther A, Fohnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nature Rev Cancer 2009, 9:489-499.
10. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr GH, Goldberg RM, Thibodeau SN. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999, 91:1295-1303. 10.1093/jnci/91.15.1295, 10433618.
11. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann Oncol 2003, 14:1026-1038. 10.1093/annonc/mdg284, 12853343.
12. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618. 10.1200/JCO.2005.01.086, 15659508.
13. Shankaran V, Wisinski KB, Mulcahy MF, Benson AB. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008, 12:87-98.
14. McHugh SM, O'Donnell J, Gillen P. Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World Journal of Surgical Oncology 2009, 7:36. 10.1186/1477-7819-7-36, 2667518, 19338662.
15. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004, 22:1564-1571. 10.1200/JCO.2004.08.186, 15051756.
16. Jiang Y, Casey G, Lavery IC, Zhang Y, Talantov D, Martin-McGreevy M, Skacel M, Manilich E, Mazumder A, Atkins D, Delaney CP, Wang Y. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008, 10:346-354. 10.2353/jmoldx.2008.080011, 2438204, 18556775.
17. de Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, Werff MP, Velde CJ, Deelder AM, Tollenaar RA. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 2006, 42:1068-1076. 10.1016/j.ejca.2005.12.023, 16603345.
18. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284. 10.1172/JCI26022, 1323259, 16395409.
19. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94:1898-1905. 10.1038/sj.bjc.6603188, 2361335, 16755300.
20. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577. 10.1016/S0140-6736(02)07746-2, 11867112.
21. Derijks-Engwegen JYMN, Cats A, Smits ME, Schellens JHM, Beijen JH. Improving colorectal cancer management: the potential of proteomics. Biomarkers in Medicine 2008, 2:253-289.
22. Gupta AK, Brenner DE, Turgeon DK. Early detection of colon cancer: new tests on the horizon. Mol Diagn Ther 2008, 12:77-85.
23. de Noo ME, Tollenaar RAEM, Deedler AM, Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: Hopes and fears. World J Gastroenterol 12:6594-6601.
24. Wang Q, Shen J, Li Z-F, Jie JZ, Wang WY, Wang J, Zhang ZT, Li ZX, Yan L, Gu J. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 2009, 9:287-296. 10.1186/1471-2407-9-287, 2743709, 19689818.
25. Xiang F, Beavis RC. Growing protein-doped sinapic acid crystals for laser desorption: an alternative preparation method for difficult samples. Org Mass Spectrom 1993, 28:6-12.
26. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005, 4:1143-1154. 10.1021/pr0500962, 16083265.
27. Mani DR, Gillette MA. Proteomic Data Analysis: Pattern Recognition for Medical Diagnosis and Biomarker Discovery. In New Generation of Data Mining Applications 2005, Kantardzic M, Zurada J.
28. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet 2006, 38:500-5011. 10.1038/ng0506-500, 16642009.
29. Gould J, Getz G, Monti S, Reich M, Mesirov JP. Comparative gene marker selection suite. Bioinformatics 2006, 22:1924-1925. 10.1093/bioinformatics/btl196, 16709585.
30. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004, 20:1453-1454. 10.1093/bioinformatics/bth078, 14871861.
31. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537. 10.1126/science.286.5439.531, 10521349.
32. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006, 116:26-30. 10.1172/JCI27467, 1323272, 16395400.
33. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006, 6:961-967. 10.1038/nrc2011, 17093504.
34. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007, 53:852-8. 10.1373/clinchem.2006.082644, 17395711.
35. Smith FM, Gallagher WM, Fox E, Stephens RB, Rexhepaj E, Petricoin EF, Liotta L, Kennedy MJ, Reynolds JV. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 2007, 245:259-266. 10.1097/01.sla.0000245577.68151.bd, 1876990, 17245180.
36. Zheng GX, Wang CX, Qu X, Deng XM, Deng BP, Zhang J. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol 2006, 28:282-287.
37. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360. 10.1016/j.ejca.2007.03.021, 17512720.